Lymphangiomyoma: Clinical Trials

11 trials for Lymphangiomyoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed. 11 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 211Completed 11
Phase 13Completed 3

Follow Lymphangiomyoma: new trials by email Literature Review of Lymphangiomyoma trials Research Report on Lymphangiomyoma

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
Sirolimus, Resveratrol - Lymphangioleiomyomatosis
Phase 2CompletedUniversity of Cincinnati252018-03-312023-02-01
LAM Pilot Study With Imatinib Mesylate
Imatinib Mesylate 400Mg Capsule, Placebo - Capsule - Lymphangioleiomyomatosis
Phase 1 / Phase 2CompletedMedical University of South Carolina182018-01-232020-06-16
Discovery of Sirolimus Sensitive Biomarkers in Blood
Sirolimus 2mg - Lymphangioleiomyomatosis
Phase 2CompletedNational Heart, Lung, and Blood Institute (NHLBI)332017-12-042026-02-18
A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
Nintedanib - Lymphangioleiomyomatosis
Phase 2CompletedIRCCS Multimedica302016-12-062022-09-28
COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
Celecoxib - Lymphangioleiomyomatosis (LAM)
Phase 2CompletedBrigham and Women's Hospital122016-06-152022-01-20
Safety of Simvastatin in LAM and TSC
Simvastatin, Sirolimus Oral Product, Everolimus Oral Product - Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Phase 1 / Phase 2CompletedUniversity of Pennsylvania102014-03-012020-08-25
Letrozole for Lymphangioleiomyomatosis
Letrozole, Placebo - Lymphangioleiomyomatosis
Phase 2CompletedUniversity of Cincinnati172011-05-012024-04-17
A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Everolimus - Lymphangioleiomyomatosis
Phase 2CompletedNovartis Pharmaceuticals242010-01-012020-11-19
RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
RAD001 - Tuberous Sclerosis, Lymphangioleiomyomatosis
Phase 1 / Phase 2CompletedChildren's Hospital Medical Center, Cincinnati362005-08-012013-09-25
Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
Rapamycin, sirolimus - Tuberous Sclerosis, Lymphangioleiomyomatosis
Phase 2CompletedChildren's Hospital Medical Center, Cincinnati252002-12-012007-04-09
Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
Octreotide - Lymphangioleiomyomatosis, Lymphangiomyomas
Phase 2CompletedNational Heart, Lung, and Blood Institute (NHLBI)42000-06-012010-04-30

Narrower conditions

Lymphangioleiomyomatosis (11)  ·  Tuberous Sclerosis (3)  ·  Ascites (1)  ·  Chylothorax (1)  ·  Chylous Ascites (1)  ·  Hereditary Sensory and Autonomic Neuropathies (1)  ·  Pleural Effusion (1)

Broader conditions

Hemic and Lymphatic Diseases (11)  ·  Immune System Diseases (11)  ·  Immunoproliferative Disorders (11)  ·  Lymphatic Diseases (11)  ·  Lymphoproliferative Disorders (11)  ·  Neoplasm, Lymphatic Tissue (11)  ·  Neoplasms (11)  ·  Neoplasms by Histologic Type (11)  ·  Neoplasms, Connective and Soft Tissue (11)  ·  Perivascular Epithelioid Cell Neoplasms (11)  ·  Congenital Abnormalities (3)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Genetic Diseases, Inborn (3)  ·  Hamartoma (3)

Interventions

Sirolimus (4)  ·  Everolimus (3)  ·  Celecoxib (1)  ·  Imatinib Mesylate (1)  ·  Letrozole (1)  ·  Octreotide (1)  ·  Resveratrol (1)  ·  Simvastatin (1)  ·  Sugars (1)  ·  nintedanib (1)

Sponsors

Children's Hospital Medical Center, Cincinnati (2)  ·  National Heart, Lung, and Blood Institute (NHLBI) (2)  ·  University of Cincinnati (2)  ·  Brigham and Women's Hospital (1)  ·  IRCCS Multimedica (1)  ·  Medical University of South Carolina (1)  ·  Novartis Pharmaceuticals (1)  ·  University of Pennsylvania (1)

Countries

United States (10)  ·  Italy (2)  ·  France (1)

Top investigators

Christopher Meinberg (1)  ·  David J Kwiatkowski, MD PhD (1)  ·  Francis X McCormack, MD (1)  ·  Frank McCormack, MD (1)  ·  Joel Moss, M.D. (1)  ·  John Bissler, MD (1)  ·  John J. Bissler, M.D. (1)  ·  Maryl Kreider, MD, MSCE (1)  ·  Nishant Gupta, MD (1)  ·  Sergio A Harari, MD (1)  ·  Vera P Krymskaya, PhD, MBA (1)

Results publications

PMID 12172553, PMID 18184959, PMID 21410393, PMID 21482669, PMID 24556663, PMID 24591665, PMID 26113676, PMID 28570161, PMID 32060062, PMID 36642366, PMID 39489895

NIH funding

R21CA103486 (1), R34HL138235 (1)